Scholar Rock wins FDA approval for Isembyld, the first drug targeting muscle loss in spinal muscular atrophy
The FDA has approved Scholar Rock's Isembyld for spinal muscular atrophy, the first therapy to address the muscle-wasting component of the disease when combined with an SMN2-targeting agent.
The US Food and Drug Administration has approved Isembyld (apitegromab), developed by Scholar Rock, for use in patients with spinal muscular atrophy (SMA). Reported by Stat News on 11 September 2026, the approval marks the first time a drug targeting skeletal muscle loss — rather than the underlying SMN protein deficit — has been cleared for SMA.
Isembyld is a selective inhibitor of myostatin, a protein that limits muscle growth. In SMA, loss of the SMN protein causes motor neuron degeneration and consequent muscle wasting; approved SMN2-targeting agents address the neurological deficit but do not directly reverse the muscle component of the disease. The pivotal trial combined Isembyld with an SMN2-targeting drug and found that patients' motor function scores improved over one year.
SMA is caused by homozygous deletion or mutation of the SMN1 gene; its severity ranges from early-onset, fatal forms to milder adult presentations. The approval adds a complementary mechanism to an already transformed treatment landscape that includes nusinersen, onasemnogene abeparvovec, and risdiplam. Details of the approved indication — including patient age range, SMA type, and required co-administration conditions — are not fully specified in the available reporting. Genetic counsellors and paediatric neurologists managing SMA patients should consult the full prescribing information.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
The US medicines regulator (the FDA) has approved a new drug called Isembyld for people with spinal muscular atrophy (SMA). SMA is a genetic condition that weakens muscles because of a fault in a gene called SMN1. Existing treatments mainly work by boosting a related gene called SMN2 to help produce more of a missing protein. Isembyld works differently — it targets a protein called myostatin that limits muscle growth, so it tackles the muscle-wasting part of SMA directly. In a clinical trial, patients who took Isembyld alongside an existing SMA medicine showed improved ability to move after one year. This approval is specific to the United States. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-09-11STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss